Online citations, reference lists, and bibliographies.

Pulmonary Neuroendocrine (carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus And Recommendations For Best Practice For Typical And Atypical Pulmonary Carcinoids.

M. Caplin, E. Baudin, P. Ferolla, P. Filosso, M. García-Yuste, E. Lim, K. Oberg, G. Pelosi, A. Perren, R. Rossi, W. Travis
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. PATIENTS AND METHODS Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical/atypical carcinoid', and 'pulmonary carcinoid and diagnosis/treatment/epidemiology/prognosis'. A systematic review of the relevant literature was carried out, followed by expert review. RESULTS PCs are well-differentiated neuroendocrine tumors and include low- and intermediate-grade malignant tumors, i.e. typical (TC) and atypical carcinoid (AC), respectively. Contrast CT scan is the diagnostic gold standard for PCs, but pathology examination is mandatory for their correct classification. Somatostatin receptor imaging may visualize nearly 80% of the primary tumors and is most sensitive for metastatic disease. Plasma chromogranin A can be increased in PCs. Surgery is the treatment of choice for PCs with the aim of removing the tumor and preserving as much lung tissue as possible. Resection of metastases should be considered whenever possible with curative intent. Somatostatin analogs are the first-line treatment of carcinoid syndrome and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC. Locoregional or radiotargeted therapies should be considered for metastatic disease. Systemic chemotherapy is used for progressive PCs, although cytotoxic regimens have demonstrated limited effects with etoposide and platinum combination the most commonly used, however, temozolomide has shown most clinical benefit. CONCLUSIONS PCs are complex tumors which require a multidisciplinary approach and long-term follow-up.
This paper references
Pulmonary tumors in the Netherlands: focus on temporal trends in histology and stage and on rare tumors
WK de Jong (2008)
Neuroendocrine neoplasms of the lung. A clinicopathologic update.
W. Warren (1989)
10.1016/j.humpath.2009.10.030
Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases.
K. Tsuta (2011)
10.3389/fendo.2011.00020
Partitioning of Bronchopulmonary Carcinoids in Two Different Prognostic Categories by Ki-67 Score
F. Grimaldi (2011)
10.1159/000111037
Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary
T. Steinmüller (2007)
10.1378/CHEST.130.5.1405
Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor.
L. Bertoletti (2006)
10.1016/0046-8177(95)90221-X
Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study.
V. Costes (1995)
10.1200/JCO.2009.22.8510
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.
R. Arnold (2009)
10.1007/BF03345602
The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers
P. Ferolla (2008)
10.1016/J.JTCVS.2005.05.041
The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors.
E. Lim (2005)
10.1016/j.jpedsurg.2010.02.070
Primary lung tumors in children and adolescents: a 90-year experience.
D. Yu (2010)
10.1007/978-3-642-60049-4
Histological Typing of Lung and Pleural Tumours
W. Travis (1999)
Neuroendocrine neoplasms of the pancreas: clinical, pathologic and cross-sectional imaging analysis according to the 4 th edition of the World Health Organization (WHO) classification of tumors of the digestive system
M. E. Abreu (2012)
10.1002/(SICI)1096-9098(199610)63:2<99::AID-JSO6>3.0.CO;2-J
Carcinoid tumors of the lung: Immuno‐ and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically
K. Kayser (1996)
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
H. Orlefors (2005)
10.1016/j.lungcan.2008.03.012
Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study.
G. Pelosi (2008)
10.1023/A:1012569909313
Experience in treatment of metastatic pulmonary carcinoid tumors.
D. Granberg (2001)
10.2967/jnumed.111.101469
Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
A. Pfeifer (2012)
RAMSETE : a single - arm , multicenter , single - stage phase II trial of RAD 001 ( everolimus ) in advanced and metastatic silent neuroendocrine tumours in Europe
ME Pavel (2012)
10.1136/thx.39.8.617
Carcinoid tumours of the bronchus: a 33 year experience.
R. Hurt (1984)
10.1016/S0016-5085(08)81267-X
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.
P. Quaedvlieg (2001)
10.1016/S1010-7940(02)00747-9
Synchronous bilateral typical pulmonary carcinoid tumors.
M. Beshay (2003)
10.1007/s00259-009-1349-9
68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours
V. Ambrosini (2009)
10.1378/CHEST.06-0711
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
C. Daniels (2007)
10.1016/J.JTCVS.2006.12.013
Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids.
H. Brokx (2007)
The clinical value of [ 90 Y-DOTA]-D-Phe1-Tyr3-octreotide ( 90 Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study
C Waldherr (2001)
fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67
R Abgral (2011)
10.1164/rccm.201010-1685PP
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview.
A. A. Nassar (2011)
10.1097/PAS.0b013e318263207c
Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods
L. Tang (2012)
10.1002/1097-0142(20010601)91:11<2104::AID-CNCR1238>3.0.CO;2-I
Familial pulmonary carcinoid tumors
A. Oliveira (2001)
10.1530/ERC-12-0050
Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?
A. Karpathakis (2012)
10.1016/1010-7940(90)90140-U
Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases.
G. Stamatis (1990)
10.1148/RADIOGRAPHICS.22.2.G02MR01351
Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings.
M. Jeung (2002)
10.1186/1471-2407-9-388
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network
M. Brizzi (2008)
International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology
P Goldstraw (2009)
10.1016/j.canep.2011.05.011
Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004.
M. Alsina (2011)
LONG-TERM FOLLOW-UP OF CLASSICAL BRONCHIAL CARCINOID TUMORS
W. Warren (1990)
10.1200/JCO.2012.30.15_SUPPL.4122
RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe.
M. Pavel (2012)
10.1016/j.suc.2010.07.001
Pulmonary assessment for general thoracic surgery.
Farzaneh Banki (2010)
A randomized, double-blind, placebocontrolled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET)
M Caplin (2013)
10.1054/bjoc.2000.1394
Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97
F. Levi (2000)
10.1159/000287277
ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors
M. Pavel (2010)
10.1309/AJCPDXFOPXGEF0RP
Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas.
K. Tsuta (2011)
Carcinoid tumors of the lung.
H. R. Carter (1987)
10.1007/s00428-012-1194-2
Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach
T. Zahel (2012)
10.1126/scitranslmed.3006802
A Genomics-Based Classification of Human Lung Tumors
D. Seidel (2013)
10.1043/1543-2165(2008)132[1079:PAMLTI]2.0.CO;2
Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital.
M. Dishop (2008)
10.1002/ijc.1473
Familial carcinoid tumors and subsequent cancers: A nation‐wide epidemiologic study from Sweden
K. Hemminki (2001)
10.1159/000225947
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography
U. Plöckinger (2009)
10.1309/ETJ3-QBUK-13QD-J8FP
Neuroendocrine neoplasia. Current concepts.
M. Wick (2000)
10.1158/1078-0432.CCR-07-1631
Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients
M. Rugge (2008)
Multi-directional differentiation of Ascl1-defined progenitors in lung development and injury repair
Y Li (2012)
10.1038/bjc.1998.635
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
E. Baudin (1998)
10.1016/S0169-5002(02)00080-6
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.
H. Skúladóttir (2002)
10.2214/AJR.170.5.9574618
Evaluation of primary pulmonary carcinoid tumors using FDG PET.
J. Erasmus (1998)
10.1136/thoraxjnl-2014-205899
Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours
Holly Pattenden (2014)
10.1002/ijc.23529
Risk factors associated with neuroendocrine tumors: A U.S.‐based case–control study
M. Hassan (2008)
10.2967/jnumed.109.066639
A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
I. Kayani (2009)
10.1097/MPA.0b013e3181ec124e
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems
D. Klimstra (2010)
10.1016/j.athoracsur.2013.05.047
Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance.
F. Lou (2013)
10.1043/1543-2165(2003)127<1200:NTCANC>2.0.CO;2
Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence.
R. Broaddus (2003)
10.1111/j.1477-2574.2010.00198.x
Long-term survival after surgical management of neuroendocrine hepatic metastases.
Evan S Glazer (2010)
10.1097/JTO.0b013e31818e0dd4
Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival
B. Skov (2008)
10.1016/J.LUNGCAN.2003.08.017
Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience.
L. Schrevens (2004)
10.1016/s0923-7534(20)33727-3
Pazonet: A Phase II Trial of Pazopanib as a Sequencing Treatment in Progressive Metastatic Neuroendocrine Tumors (NETS) Patients (PTS), On Behalf of The Spanish Task Force for Nets (GETNE)
E. Grande (2012)
10.1016/j.ejca.2013.12.011
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
T. Meyer (2014)
10.1016/j.echo.2003.08.001
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca
M. Cheitlin (2003)
10.1097/00000478-199506000-00005
Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors.
R. Miller (1995)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.1378/chest.94.1.15
Nd:YAG laser bronchoscopy. A five-year experience with 1,396 applications in 1,000 patients.
S. Cavaliere (1988)
10.1200/JCO.2007.13.6374
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
J. Yao (2008)
August 2015 doi:10.1093/annonc/mdv041 |  Annals of Oncology special articles
10.1159/000183751
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy
K. Öberg (2008)
10.1016/s0022-5223(19)35513-8
Neuroendocrine neoplasms of the lung.
J. Benfield (1990)
10.2967/jnumed.106.035667
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
M. Gabriel (2007)
International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. Florida, USA: Editorial
P. Goldstraw (2009)
special articles Annals of Oncology
Caplin (2015)
10.1007/s00268-005-0774-6
7201 Carcinoids: Increasing Incidence Overall and Disproportionate Mortality in the Elderly
E. Perez (2005)
10.1159/000201197
Revised classification of neuroendocrine tumors of the lung, pancreas and gut.
C. Capella (1994)
10.1200/JCO.2010.33.7873
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
A. Imhof (2011)
10.1016/S1010-7940(02)00055-6
Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
P. Filosso (2002)
Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties.
J. Soga (1999)
: a baseline and two - year repeat study
BI Gustafsson (2008)
10.1183/2312508x.erm6815
Lung cancer.
H. Hansen (1990)
10.1016/j.athoracsur.2008.04.115
Clinical application of direct bronchial ultrasound to visualize and determine endobronchial tumor margins for surgical resection.
K. Sarraf (2008)
10.1016/J.LUNGCAN.2006.12.001
Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening.
D. Carter (2007)
10.1016/j.clinimag.2011.11.011
What is DIPNECH?
C. Walker (2012)
10.1097/01.pas.0000149690.75462.29
Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens: A Major Pitfall in the Management of Lung Cancer Patients
G. Pelosi (2005)
10.1002/cncr.23542
Bronchopulmonary neuroendocrine tumors
B. Gustafsson (2008)
10.1038/sj.bjc.6605618
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
N. Turner (2010)
August 2015 doi:10.1093/annonc/mdv041 |  Annals of Oncology special articles
Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC
W Travis (2004)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1016/S0959-8049(01)00073-9
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
T. Aparicio (2001)
10.1210/jc.2012-1230
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).
R. Thakker (2012)
10.1210/JC.2004-1938
Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography
H. Örlefors (2005)
10.1002/1097-0142(19871115)60:10<2476::AID-CNCR2820601022>3.0.CO;2-R
Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors
R. Greenberg (1987)
10.1164/AJRCCM.185.3.341A
mTOR/p70S6K in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
D. Jaroszewski (2012)
10.1200/JCO.2003.12.142
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
S. Faiss (2003)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1097/PAS.0b013e318158a397
Islet 1 (Isl1) Expression is a Reliable Marker for Pancreatic Endocrine Tumors and Their Metastases
A. Schmitt (2008)
Pulmonary Neuroendocrine Carcinomas
Qin Zhen Huang (2009)
10.1043/0003-9985(2002)126<0545:PNC>2.0.CO;2
Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification.
Q. Huang (2002)
10.1016/J.EJCTS.2006.11.031
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.
M. García-Yuste (2007)
10.2214/AJR.10.5954
CT features of peripheral pulmonary carcinoid tumors.
Q. Meisinger (2011)
10.3109/14017438909106008
Bronchopulmonary carcinoids in Iceland 1955-1984. A retrospective clinical and histopathologic study.
J. G. Hallgrímsson (1989)
10.1677/ERC.0.0100437
Genetics of neuroendocrine and carcinoid tumours.
P. D. Leotlela (2003)
10.1378/CHEST.123.1_SUPPL.129S
Diagnosis of lung cancer: the guidelines.
M. Rivera (2003)
10.1201/9780203912997.CH5
The Neuroendocrine Lung
J. Gosney (2003)
10.1097/JTO.0b013e31818b06e3
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
W. Travis (2008)
10.1159/000335597
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
M. Pavel (2011)
Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.
M. Kulke (2009)
10.1043/2009-0583-RAR.1
Neuroendocrine tumors of the lung: an update.
N. Rekhtman (2010)
10.1111/j.1572-0241.2000.03210.x
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
M. Ducreux (2000)
10.3109/14017439009098055
Long-term follow-up of classical bronchial carcinoid tumors. Clinicopathologic observations.
W. Warren (1990)
10.1136/thx.2007.095067
Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours
W. D. de Jong (2008)
ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
K Öberg (2012)
10.1016/J.YPED.2011.06.042
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
J. A. Stockman (2012)
10.1097/JTO.0b013e318206a221
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
W. Travis (2011)
10.1210/jc.2008-0459
Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
S. Leboulleux (2008)
10.1210/jc.86.12.5658
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
M. Brandi (2001)
10.1002/cncr.20825
Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1
N. Sachithanandan (2005)
10.1055/s-0029-1202857
Bronchial carcinoid tumours in children: surgical treatment and outcome in a single institution.
G. Rizzardi (2009)
J Clin Oncol
(2008)
RAMSETE : a single - arm , multicenter , single - stage phase II trial of RAD 001 ( everolimus ) in advanced and metastatic silent neuroendocrine tumours in Europe
E Raymond (2012)
10.1309/AJCP9H1OTMUCSKQW
Neuroendocrine carcinomas of the lung: a critical analysis.
C. Moran (2009)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
J. Yao (2008)
10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R
Incidence trends and risk factors of carcinoid tumors
K. Hemminki (2001)
10.1159/000184855
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations
A. Sundin (2008)
10.1016/j.athoracsur.2010.08.062
Bronchopulmonary carcinoid tumors: long-term outcomes after resection.
C. Cao (2011)
10.1023/A:1011160913619
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
C. Waldherr (2001)
10.1002/cncr.23883
Neuroendocrine tumor epidemiology
O. Hauso (2008)
10.3275/8102
Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY
A. Faggiano (2011)
10.1520/STP13641S
Performance of A 3 MCNP™ for Calculation of 3-D Neutron Flux Distribution in a BWR Core Shroud
A. Haghighat (2001)
10.1530/ERC-13-0246
Grading the neuroendocrine tumors of the lung: an evidence-based proposal.
G. Rindi (2014)
10.1097/JTO.0b013e318221f54f
Tumorlets in familial history of bronchopulmonary carcinoid.
Ugo De Giorgi (2011)
10.1016/S0140-6736(11)61742-X
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
M. Pavel (2011)
10.1200/JCO.2008.20.3034
Activity of sunitinib in patients with advanced neuroendocrine tumors.
E. Bajetta (2009)
10.1007/s00330-012-2615-y
Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases
P. Bhosale (2012)
10.1016/J.LUNGCAN.2003.11.016
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
L. Wirth (2004)
10.1007/s00428-013-1408-2
Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids
A. Warth (2013)
10.1016/S0046-8177(98)90047-8
Reproducibility of neuroendocrine lung tumor classification.
W. Travis (1998)
10.1148/rg.291085126
Tumors in the tracheobronchial tree: CT and FDG PET features.
Chang Min Park (2009)
10.1210/JCEM.86.12.8070
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
M. Brandi (2001)
10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
E. Bajetta (1999)
10.1046/j.1365-2265.2003.01931.x
Octreoscan in patients with bronchial carcinoid tumours
D. Granberg (2003)
10.1002/dc.21296
Melanocytic bronchopulmonary carcinoid tumor in a patient with multiple endocrine neoplasia syndrome type 1: A case report with emphasis on intraoperative cytological findings
Kant M. Matsuda (2010)
10.1093/ANNONC/MDS267
Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
K. Öberg (2012)
10.1378/CHEST.119.6.1647
Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.
G. Fink (2001)
10.1007/s00428-011-1118-6
Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2
G. Hermann (2011)
10.1200/JCO.2011.40.3147
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Jennifer A. Chan (2012)
10.1016/1010-7940(90)90168-Y
Low grade neuroendocrine tumors of the lung (bronchial carcinoids)--25 years experience.
F. Francioni (1990)
10.1002/cncr.24498
Pulmonary neuroendocrine/carcinoid tumors
E. Bertino (2009)
10.1016/J.EJCTS.2006.05.013
Metachronous bronchial carcinoid tumor.
F. Rea (2006)
10.1007/s00280-006-0306-6
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
E. Bajetta (2006)
10.1200/JCO.2005.03.616
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
W. Sun (2005)
International association for the study of lung cancer International Multidisciplinary Classification of lung adenocarcinoma
W Travis (2011)
10.1002/cncr.11105
A 5‐decade analysis of 13,715 carcinoid tumors
I. Modlin (2003)
10.1002/1097-0142(197009)26:3<547::AID-CNCR2820260307>3.0.CO;2-J
Management of carcinoid tumors
R. G. Martin (1970)
10.1097/JTO.0b013e318197f2e7
Tumorlets, Multicentric Carcinoids, Lymph-Nodal Metastases, and Long-Term Behavior in Bronchial Carcinoids
P. Ferolla (2009)
10.1016/S0923-7534(20)33726-1
Ramsete : a single-arm, multicenter, single-stage phase ii trial of rad001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in europe: analysis by tumor origin
M. Pavel (2012)
10.1097/MPA.0b013e3181ec1380
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)
A. Phan (2010)
10.1038/modpathol.2012.81
Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors
A. Walts (2012)
10.1053/HUPA.2000.19294
Pulmonary atypical carcinoid: predictors of survival in 106 cases.
M. Beasley (2000)
10.1097/MNM.0b013e32832999c1
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid
V. Ambrosini (2009)
10.1007/s00259-006-0355-4
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
M. Essen (2006)
10.1159/000287255
ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors
B. Kos-Kudła (2010)
10.2214/AJR.09.3811
Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids.
C. W. Koo (2010)
10.1007/BF00199342
Revised classification of neuroendocrine tumours of the lung, pancreas and gut
C. Capella (2004)
10.1097/JTO.0b013e3181861d7b
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007
E. Lim (2008)
10.2967/jnumed.109.066134
The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
R. Srirajaskanthan (2010)
10.1016/J.EJCTS.2004.05.052
Surgical treatment of neuroendocrine tumors of the lung.
Niccolò Daddi (2004)
10.1016/S0925-4773(99)00325-1
The molecular basis of lung morphogenesis
D. Warburton (2000)
10.1097/JTO.0b013e3181ca063b
ERCC1 and Ki67 in Small Cell Lung Carcinoma and Other Neuroendocrine Tumors of the Lung: Distribution and Impact on Survival
B. Skov (2010)
10.1159/000227552
Bronchial carcinoids. A review of 22 cases.
M. Froudarakis (1996)
10.1677/ERC-10-0024
Paraneoplastic syndromes secondary to neuroendocrine tumours.
G. Kaltsas (2010)
10.1002/1097-0142(197710)40:4<1671::AID-CNCR2820400441>3.0.CO;2-O
Comparative epidemiology of carcinoid and oat‐cell tumors of the lung
J. Godwin (1977)
10.1210/jc.2010-2022
Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging.
Ronan Abgral (2011)
10.1016/1010-7940(93)90140-7
Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients.
P. Vadász (1993)
10.1200/JCO.2007.15.2553
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
D. Kwekkeboom (2008)
10.1093/annonc/mdp334
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
L. Righi (2010)
Typical and atypical carcinoid : analysis of the experience of the Spanish multicenter study of neuroendocrine tumors of the lung
M García-Yuste (2007)
10.1007/978-3-642-59655-1
Histological Typing of Endocrine Tumours
E. Solcia (2000)
10.1165/rcmb.2012-0027OC
Multidirectional differentiation of Achaete-Scute homologue-1-defined progenitors in lung development and injury repair.
Y. Li (2012)
10.1007/s00428-006-0250-1
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
G. Rindi (2006)
10.1016/J.CCR.2005.08.008
The Akt-mTOR tango and its relevance to cancer.
N. Hay (2005)
10.1634/THEONCOLOGIST.10-2-123
Metastatic carcinoid tumors: a clinical review.
J. M. Zuetenhorst (2005)
10.1164/AJRCCM.185.3.341
mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
G. Rossi (2012)
10.1111/j.1365-2559.2011.03992.x
Morphology and antigen expression profile of pulmonary neuroendocrine cells in reactive proliferations and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
J. Gosney (2011)
10.1002/PBC.20279
Primary epithelial lung malignancies in the pediatric population.
D. Lal (2005)
10.1046/j.1365-2559.2002.01336.x
Neuroendocrine differentiation and prognosis in breast adenocarcinoma
A. Miremadi (2002)
10.1038/labinvest.3700412
Functional facets of the pulmonary neuroendocrine system
R. I. Linnoila (2006)
10.1016/j.ejcts.2010.08.036
Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study.
A. Naalsund (2011)
Pulmonary tumors in the Netherlands: focus on temporal trends in histology and stage and on rare tumors
Wk De Jong (2008)
Neuroendocrine neoplasia
MR Wick (2000)
10.4103/1817-1737.43082
Diagnosis of peripheral pulmonary carcinoid tumor using endobronchial ultrasound
Daniel P Steinfort (2008)
10.1093/ANNONC/12.SUPPL_2.S115
Clinical significance of neuroendocrine carcinoma of the breast.
A. Sapino (2001)
10.1016/S1010-7940(03)00287-2
Synchronous bilateral lung carcinoid tumors: a rare entity?
L. Spaggiari (2003)
10.1016/j.ejca.2013.06.042
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
D. Castellano (2013)
10.1111/j.1365-2036.2009.04174.x
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
I. Modlin (2010)
10.1056/NEJMoa1003825
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
E. Raymond (2011)
10.1067/MTC.2002.119886
Bronchial carcinoid tumors: surgical management and long-term outcome.
P. Filosso (2002)
10.1002/cncr.22694
Author reply
A. Goy (2007)



This paper is referenced by
10.2147/CMAR.S113382
Emerging use of everolimus in the treatment of neuroendocrine tumors
P. Gajate (2017)
10.4414/FMS.2016.02604
Tumeurs neuroendocrines pulmonaires
Dirk Kleindienst (2016)
10.1016/j.jtcvs.2017.09.068
New staging system for pulmonary neuroendocrine tumors: A clinical and pathologic necessity.
Ming-Ching Lee (2018)
10.17925/EOH.2015.11.02.100
Mammalian target of rapamycin (mTOR) inhibition in advanced bronchial carcinoids
Nicola Fazio (2015)
10.1016/j.lungcan.2015.08.018
Systemic therapy for pulmonary carcinoids.
Diego Márquez-Medina (2015)
10.3904/KJM.2016.90.1.7
Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma
Jung Hye Kwon (2016)
10.1097/MD.0000000000007870
Cushing's syndrome secondary to typical pulmonary carcinoid with mutation in BCOR gene
Yimin A Wu (2017)
University of Southern Denmark Lung cancer in younger patients Abbasowa,
Poul Henning (2016)
10.1007/978-3-319-92216-4_19
Making the Diagnosis of Neuroendocrine Tumour Disease
Vandana Mridhu Sagar (2019)
10.1016/S1877-1203(18)30029-6
Tumeurs neuro-endocrines broncho-pulmonaires primitives: tumeurs carcinoïdes et carcinomes neuro-endocrines à grandes cellules
Pierre-Jean Souquet (2018)
10.1530/ERC-17-0269
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
V. Marotta (2018)
10.1093/ejcts/ezaa018
Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy.
P. Filosso (2020)
10.1159/000497037
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
A. Malczewska (2019)
10.1016/j.jval.2016.09.2218
Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective
Amélie Perrin (2016)
10.1007/s00117-019-0574-x
Neuroendokrine Tumoren
Hans Scheruebl (2019)
10.1007/978-3-030-27233-3
The Thorax
Daniele Regge (2020)
10.1007/s11154-020-09552-x
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
Julie Refardt (2020)
10.1007/s11154-018-9442-7
Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines
S. Petersenn (2018)
10.1136/bmjopen-2016-012530
Patient characteristics, treatment and survival in pulmonary carcinoid tumours: an analysis from the UK National Lung Cancer Audit
S. Hobbins (2016)
10.1155/2018/1043287
Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries
A. Agasarova (2018)
10.1530/EDM-19-0033
Pulmonary embolism as the presenting symptom and a confounder in ACTH-secreting bronchial carcinoid
W. Yang (2019)
10.1016/j.clon.2015.02.009
Bronchopulmonary neuroendocrine tumours.
Nicholas Simon Reed (2015)
10.1186/s13256-017-1234-2
Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report
Zareen Kiran (2017)
10.7196/SARJ.2018.v24i2.209
Complete lung collapse in a young adolescent
Tawheed Hassan Ahmed (2018)
10.31487/J.RCO.2018.01.001
Mini-review: Current challenges in the treatment of developmentally diverse neuroendocrine like tumors: Comparison of bronchial carcinoids and neuroblastoma
Evgeniya Morgatskaya (2019)
10.3779/j.issn.1009-3419.2019.08.03
[Surgical Resection and Prognosis of Bronchopulmonary Carcinoid].
Shaowei Zhang (2019)
10.1042/BSR20194127
Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis
Zhirong Qi (2020)
10.1186/s12885-019-6018-1
Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane
Reza Bayat Mokhtari (2019)
10.1016/j.ijscr.2020.05.043
Multiple liver metastases of pulmonary carcinoid successfully treated by two-stage hepatectomy combined with embolization of portal vein branches: Report of a case
T. Kamada (2020)
10.1016/j.athoracsur.2018.05.044
Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases.
P. Kneuertz (2018)
10.1016/j.jtho.2018.02.002
New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management
J. Derks (2018)
10.18632/oncotarget.27659
Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
L. E. Lim (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar